Related Experiment Video
Updated: Jul 28, 2026

Propagation of Homalodisca coagulata virus-01 via Homalodisca vitripennis Cell Culture
Published on: September 25, 2014
Relationship between glucocorticoids and viral load during the Omicron wave in mainland China
Guangxu Bai1,2, Yan Li1,2, Yang Liu1,2
1Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100730, China.
Insights
Glucocorticoids did not accelerate coronavirus disease 19 (COVID-19) viral clearance or affect mortality. However, glucocorticoid therapy may aid in COVID-19 negative conversion and reduce inflammatory factors, potentially by regulating the immune response.
Area of Science:
- Infectious Diseases
- Pharmacology
- Immunology
Background:
- Coronavirus disease 19 (COVID-19) remains a significant global health concern.
- The role of glucocorticoids in COVID-19 treatment, specifically regarding viral clearance and patient prognosis, is debated.
- This study investigates the association between glucocorticoid use and COVID-19 viral load.
Purpose of the Study:
- To examine the relationship between glucocorticoid therapy and COVID-19 viral load dynamics.
- To assess the impact of glucocorticoids on viral clearance and patient outcomes in COVID-19.
- To understand the potential immunomodulatory effects of glucocorticoids in COVID-19 patients.
Main Methods:
- Retrospective analysis of COVID-19 patients admitted to Peking Union Medical College Hospital (late 2022-early 2023).
- Collection of baseline, clinical, laboratory, immunological, and daily viral load data.
- Statistical analysis using Kolmogorov-Smirnov test, Student's t test, Mann-Whitney U test, and Cox proportional-hazards model.
Main Results:
- Glucocorticoids did not significantly alter COVID-19 viral clearance, replication, or 28-day/in-hospital mortality.
- Glucocorticoid therapy was associated with a favorable factor for COVID-19 negative conversion in the Cox model.
- Patients on glucocorticoids exhibited significantly decreased levels of inflammatory factors.
Conclusions:
- Glucocorticoids may not directly impact SARS-CoV-2 viral load but could improve clinical symptoms.
- The therapeutic benefit of glucocorticoids might stem from modulating the immune response to inflammatory storms.
- Further research into the immunoregulatory mechanisms of glucocorticoids in COVID-19 is warranted.
Background:
Coronavirus disease 19 (COVID-19) is a major public health problem that cannot be ignored. As a widely used drug in the treatment of COVID-19, whether glucocorticoids may accelerate the clearance of COVID-19 is still not clear, and the glucocorticoids may improve the prognosis of patients is also controversial. Therefore, to explore the relationship between COVID-19 viral load and the use of glucocorticoids we designed this study.
Methods:
Patients with COVID-19 infection who were admitted to the emergency department of Peking Union Medical College Hospital from the end of 2022 to early 2023 were enrolled in this study. Characteristics of baseline, clinical and laboratory evaluation especially immunological indicator and daily viral load were carefully collected. Kolmogorov-Smirnov test, Student's t test, Mann-Whitney U test and proportional-hazards model (Cox model) were chosen as appropriate for comparison of variables.
Results:
By comparing the daily COVID-19 viral load and prognosis of patients with and without glucocorticoid therapy, we found that glucocorticoids did not statistically enhance the clearance or replication of COVID-19, nor did it change the 28-days and in-hospital mortality. However, glucocorticoid therapy may be a favorable factor for COVID-19 negative conversion in Cox model. The inflammatory factors in patients with glucocorticoid therapy were significantly decreased.
Conclusions:
We believe that the real effect of glucocorticoids may be to improve the destruction of host immune system caused by inflammatory storm through host immune regulation and then achieve the improvement of clinical symptoms.
More Related Videos
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
06:29Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Subviral Agents
Cytomegalovirus Disease
Coronavirus
Inhibitors of Viral Protein Synthesis